JPMorgan's Dimon: Healthcare initiative may be more about smaller steps than moon shots

Nicholas Leider | | Health Exec | Management
update policy

It’s natural to expect great things from an initiative attached to three corporate giants, but Jamie Dimon is calling for folks to temper their expectations for the initiative that includes his JPMorgan Chase, Warren Buffett’s Berkshire Hathaway and Jeff Bezos’ Amazon. The trio’s goal is to improve healthcare for their 1.1 million employees, but details surrounding the project have been scant.

"This is an absolute critical issue and all of us have a long-term view and we've been through the amount of money spent on fraud, administration, end-of-life, the misuse of drugs," and others, Dimon told CNBC's Wilfred Frost. "I'll remind people that Jeff Bezos, when he started Amazon, he might have had visions about the 'everything store,' but he started with books. And he spent 10 years getting books right."

Check out a brief interview with Dimon at CNBC at the link below:

Jamie Dimon says health care initiative with Buffett and Bezos may start small …

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.